What is the typical AOD-9604 dose?
Preclinical AOD-9604 research protocols typically use 300-500 mcg per dose on a once-daily subcutaneous schedule across 4-12 week protocols. Joint-research protocols use lower-volume intra-articular injection at the affected joint rather than systemic subcutaneous administration.
What the research literature says
AOD-9604’s metabolic-research dose framework derives from the early Heffernan series — oral administration effects on lipid metabolism (PMID 10950816) and chronic-treatment effects on fat oxidation and weight loss in obese mice (PMID 11673763). The Wilding drug-evaluation review (PMID 15134286) consolidates the early development and clinical-pharmacology framework that anchors the 300-500 mcg per-dose systemic range.
The Kwon rabbit-osteoarthritis intra-articular injection work (PMID 26275694) used a different administration framework — direct injection into the affected joint at lower per-dose volumes than systemic subcutaneous protocols would require. Researchers studying joint-research applications should anchor protocol design to the published intra-articular framework rather than to the systemic-administration framework.
The compound’s research base is smaller than the broader GH-axis research peptides — protocols extending beyond the published 4-12 week framework may not be well-supported by the existing literature.
Why this matters in research context
AOD-9604’s dose framework is narrower than the broader GH-axis class because the compound’s research literature is smaller and less recent. Researchers should anchor protocol design to the specific Heffernan or Wilding framework being replicated rather than extrapolating beyond the studied dose ranges.
Related compounds
- AOD-9604 5mg — the compound covered by this answer
Related research questions
References
- Heffernan MA et al. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab 2000;279(3):E501-E507. [PMID 10950816]
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord 2001;25(10):1442-1449. [PMID 11673763]
- Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs 2004;5(4):436-439. [PMID 15134286]
- Kwon DR et al. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci 2015;45(4):426-432. [PMID 26275694]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. AOD-9604 is sold strictly as a research-grade reagent for laboratory and bench research applications.